Mydecine Innovations Group Inc.
MYCOF
$0.10
-$0.14-59.53%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -114.22% | -68.10% | -42.89% | -64.39% | -39.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -106.71% | -89.34% | -44.14% | -179.88% | 82.09% |
| Operating Income | 106.71% | 89.34% | 44.14% | 179.88% | -82.09% |
| Income Before Tax | 103.67% | 99.52% | 72.37% | 136.16% | -65.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 103.67% | 99.52% | 72.37% | 136.16% | -65.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.67% | 99.52% | 72.37% | 136.16% | -65.51% |
| EBIT | 106.71% | 89.34% | 44.14% | 179.88% | -82.09% |
| EBITDA | -- | -- | -- | 179.97% | -82.07% |
| EPS Basic | 103.67% | 99.52% | 75.92% | 129.02% | 22.95% |
| Normalized Basic EPS | 103.67% | 95.11% | 60.54% | 117.68% | 22.95% |
| EPS Diluted | 103.67% | 99.52% | 75.92% | 129.02% | 22.95% |
| Normalized Diluted EPS | 103.67% | 95.11% | 60.54% | 117.68% | 22.95% |
| Average Basic Shares Outstanding | 0.00% | 0.92% | 14.78% | 24.61% | 114.80% |
| Average Diluted Shares Outstanding | 0.00% | 0.92% | 14.78% | 24.61% | 114.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |